Table 3 ICI combination therapy with CXCR4 blockade in cancer therapy
From: Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Tumor | Target IC | Result | References |
|---|---|---|---|
Hepatocellular carcinoma | PD-1 | Inhibition of tumor growth and lung metastasis along with improved OS rate in mice models | [231] |
Triple-negative breast cancer | PD-L1 | Robust antitumor effect and extended OS rate in 4T1 cell bearing murine model | [235] |
Ovarian cancer | PD-1 | Enhancing the effector T-cell infiltration, improving effector T-cell function and also memory T cells in TME Reducing intratumoral Treg cells and promoting the conversion of Treg cells into T helper Improved OS rate in mice model | [233] |
Glioblastoma | PD-1 | Improving the memory T cells and reducing MDSCs Promoting CD4 + /CD8 + ratios in the brain and elevation of pro-inflammatory cytokines levels in the brain | [36] |
Pancreatic ductal adenocarcinoma | PD-1 | Inspiring the CD8 + T-cell migration into the juxtatumoral compartment and also induction apoptosis in tumor cell | [237] |
Osteosarcoma | PD-1 | Inducing tumor regression by suppressing MDSCs in mice model | [232] |
Colon cancer Melanoma | PD-1 | Inhibition of tumor growth in two syngeneic murine models, by improving granzyme and suppressing FOXP3 cells infiltration | [236] |
Ovarian cancer | PD-1 | Improved OS rate in treated mice model | [234] |
Lung cancer | PD-L1 | Improving the T cell infiltration, enhancing expression of calreticulin on tumor cells Reducing MDSCs and Treg in the TME | [274] |
Glioblastoma | PD-1 | Demonstrating immune memory concurrently reducing populations of MDSCs and tumor-promoting immune cells Improved OS rate in treated mice model | [275] |
Triple-negative breast cancer | PD-L1 | Promoting the tumor immunogenicity to recruit T cells, attenuating the physiological barricades of intratumoral fibrosis and collagen to support T cell infiltration, and reducing the immunosuppressive cells to revive T cells | [276] |
Melanoma | PD-1 | Modulating the immune cell profile within the TME and improving CD8 + T cell infiltration | [277] |